受国际权威法律评级机构钱伯斯(Chambers and Partners)邀请，环球律师事务所已连续第七年为其独家撰写《全球法律指南：生命科学2024》之中国篇。该指南中各个国家与地区的篇章均由钱伯斯排行榜中该专业领域的领先律所撰写，旨在简明扼要地介绍各司法辖区内该专业领域法律和实务上的最新发展和趋势。

Chambers and Partners, one of the most authoritative international legal ranking agencies, invited Global Law Office to exclusively contribute to the Life Sciences 2024, China: Law & Practice for the seventh consecutive year. The China chapter is one of the individual chapters of the Chambers Global Practice Guide Series. Each country chapter has been contributed by editors from leading firms ranked by Chambers and Partners. It aims to provide a concise navigation of the latest legal system in the jurisdiction and the developments and trends of legal practice in this area in each jurisdiction.

此次《全球法律指南：生命科学2024》之中国篇由环球律师事务所周磊、范可、王舒雯、曹思思、袁修远、张旭东、代润霖、徐瑞苑撰写，聚焦中国法下的生命科学与医药健康领域法律重点，从法律监管框架、临床试验、药品和医疗器械上市许可、药品和医疗器械制造、药品和医疗器械分销、药品和医疗器械进出口、药品和医疗器械定价及报销、数字医疗、专利、其他知识产权等多个话题进行阐述并做详细的分析与解读。文章结合了环球生命科学及医疗团队在该领域的丰富实务经验与研究成果，希望能够为企业在中国合法、合规地开展相关活动提供有价值、有深度、有层次的实务指引。如果您希望就本指南或就本指南所讨论的内容做进一步交流，敬请联系撰文作者。

The Life Sciences 2024, China: Law & Practice is written by legal professionals of Global Law Office, Lei (Alan) Zhou, Ke (Coco) Fan, Shuwen (Stephanie) Wang, Sisi (Kelly) Cao, Xiuyuan Yuan, Xudong (Vick) Zhang, Runlin (Lynne) Dai, Ruiyuan Xu. It outlines major legal issues and topics in Life Sciences and Healthcare areas under Chinese law, and introduces the regulatory framework of China’s Life Sciences practice, clinical trials, marketing authorizations of pharmaceutical and medical devices, manufacturing of pharmaceutical and medical devices, distribution of pharmaceuticals and medical devices, importation and exportation of pharmaceuticals and medical devices, pharmaceuticals and medical device pricing and reimbursement, digital healthcare, patents and IP and other than patents, and etc. By combining the rich experience of Global Law Office’s Life Sciences and Healthcare team, this chapter aims to provide a comprehensive perspective on the landscape of China’s Life Sciences sector, and practical guidelines for global and local pharmaceutical companies to conduct business activities in China in a legal and compliant manner. Should you have inquiries or comments regarding the publication, please feel free to contact the authors.